Heron Therapeutics (HRTX)
1.7700 +0.0400 (+2.31%) 02/24/25 [NASDAQ]
1.7600 x 100 1.8900 x 100
Realtime by (Cboe BZX)
1.7600 x 100 1.8900 x 100
Realtime 1.7500 -0.0200 (-1.13%) 18:01 ET
for Mon, Feb 24th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
Sales | 127,044 | 107,672 | 86,346 | 88,638 | 145,968 |
Cost of Goods | 65,105 | 54,874 | 46,021 | 36,189 | 61,619 |
Gross Profit | 61,939 | 52,798 | 40,325 | 52,449 | 84,349 |
Operating Expenses | 172,659 | 228,330 | 258,174 | 280,801 | 295,662 |
Operating Income | -110,615 | -174,658 | -217,828 | -228,163 | -210,694 |
Interest Expense | 3,868 | 2,474 | 2,410 | 1,901 | 1,472 |
Other Income | 3,924 | -4,892 | -445 | 2,786 | 7,417 |
Pre-tax Income | -110,559 | -182,024 | -220,683 | -227,278 | -204,749 |
Net Income Continuous | -110,559 | -182,024 | -220,683 | -227,278 | -204,749 |
Net Income | $-110,559 | $-182,024 | $-220,683 | $-227,278 | $-204,749 |
EPS Basic Total Ops | -0.80 | -1.67 | -2.24 | -2.50 | -2.50 |
EPS Basic Continuous Ops | -0.80 | -1.67 | -2.24 | -2.50 | -2.50 |
EPS Diluted Total Ops | -0.80 | -1.67 | -2.24 | -2.50 | -2.50 |
EPS Diluted Continuous Ops | -0.80 | -1.67 | -2.24 | -2.50 | -2.50 |
EPS Diluted Before Non-Recurring Items | -0.80 | -1.67 | -2.24 | -2.50 | -2.50 |
EBITDA(a) | $-109,116 | $-172,303 | $-213,571 | $-223,762 | $-211,330 |